New neurotechnology applications require a new platform - so we built one.
Why?
We've reimagined the neural interface, building products that are compatible with the future of minimally-invasive surgery
Our technology opens the door to entirely new indications for BCI
Our tiny, powerful neural interfaces are designed to enable new treatment possibilities with minimal surgery. Our first technology program is SOMA-1.
A batteryless, optical BCI platform, unlocking a new scale of miniaturisation and whole brain coverage.
Discreet, a low power budget, and high data rates by leveraging high-bandwidth optical communication.
We harness the wealth of brain data, to discover new biomarkers, drive intervention faster and explore new therapeutic targets.
Opto's flagship neurotechnology platform is smaller than any other on the market, enabled by novel electrode materials, batteryless operation, and advancing manufacturing methods.
We’re creating a safer, minimally invasive device, without compromising on features.
Our platform conforms to the body using ultra-flexible materials which mimic the natural properties of biological tissue. This enables higher electrode coverage, higher electrode count and longer-term integration with the body.
This will unlock whole brain interfacing.
Our platform is designed to elicit minimal MRI artefact. This unlocks training against MRI data not possible with the technology of today and the application of neural interfaces in diseases where MRI is essential and inevitable.
The only BCI than can capture real-time electrical and imaging data
To enable a new generation of treatment efficacy and therapeutics data is key. Opto's platform extracts high fidelity electrical information from the body, using machine learning to derive neural biomarkers associated with patient specific disease state and treatment efficacy. Clinicians will soon be able to see on-demand, real-time, and remote electrophysiological maps of the patients brain during and throughout treatment.
